FDA publishes Alexion's response letter; Arena can finally launch Belviq;

> Brazil's Anvisa says it will publish new excipient guidelines that will be more in line with those in the U.S. and Europe. Story

> Here is a highly redacted copy of Alexion's ($ALXN) response to the FDA's recent Form 483 for the company posted on the FDA website. Letter (PDF)

> Stanley C. Weisser, R.Ph., president of the California Board of Pharmacy provides his take on proposed federal track and trace legislation that would preempt the California law set to go into effect in 2015. Blog post

> CMI Cosmetic Manufacturers in Ontario, Canada, has received an FDA warning letter for failing to register and for a list of problems in the manufacturing of its over-the-counter drugs. Letter

And Finally... The Drug Enforcement Agency has finally given a schedule designation to weight-loss drug Belviq so that Arena Pharmaceuticals ($ARNA) can finally move forward next month with the launch. Story

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.